<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35454873</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2072-6694</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>14</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancers</Title>
          <ISOAbbreviation>Cancers (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8<sup>+</sup> T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1970</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers14081970</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current treatments for castrate (hormone)-resistant prostate cancer (CRPC) remain limited and are not curative, with a median survival from diagnosis of 23 months. The PAP-specific Sipuleucel-T vaccine, which was approved by the FDA in 2010, increases the Overall Survival (OS) by 4 months, but is extremely expensive. We have previously shown that a 15 amino accid (AA) PAP sequence-derived peptide could induce strong immune responses and delay the growth of murine TRAMP-C1 prostate tumors. We have now substituted one amino acid and elongated the sequence to include epitopes predicted to bind to several additional HLA haplotypes. Herein, we present the immunological properties of this 42mer-mutated PAP-derived sequence (MutPAP42mer).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The presence of PAP-135-143 epitope-specific CD8<sup>+</sup> T cells in the blood of patients with prostate cancer (PCa) was assessed by flow cytometry using Dextramer™ technology. HHDII/DR1 transgenic mice were immunized with mutated and non-mutated PAP-derived 42mer peptides in the presence of CAF<sup>®</sup>09 or CpG ODN1826 (TLR-9 agonist) adjuvants. Vaccine-induced immune responses were measured by assessing the proportion and functionality of splenic PAP-specific T cells in vitro.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">PAP-135-143 epitope-specific CD8<sup>+</sup> T cells were detected in the blood of patients with PCa and stimulation of PBMCs from patients with PCa with mutPAP42mer enhanced their capacity to kill human LNCaP PCa target cells expressing PAP. The MutPAP42mer peptide was significantly more immunogenic in HHDII/DR1 mice than the wild type sequence, and immunogenicity was further enhanced when combined with the CAF<sup>®</sup>09 adjuvant. The vaccine induced secretory (IFNγ and TNFα) and cytotoxic CD8<sup>+</sup> T cells and effector memory splenic T cells.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The periphery of patients with PCa exhibits immune responsiveness to the MutPAP42mer peptide and immunization of mice induces/expands T cell-driven, wild-type PAP immunity, and therefore, has the potential to drive protective anti-tumor immunity in patients with PCa.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vu</LastName>
            <ForeName>Pauline Le</ForeName>
            <Initials>PL</Initials>
            <AffiliationInfo>
              <Affiliation>The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vadakekolathu</LastName>
            <ForeName>Jayakumar</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Health, Ageing and Understanding Disease (CHAUD), School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Idri</LastName>
            <ForeName>Sarra</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicholls</LastName>
            <ForeName>Holly</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cavaignac</LastName>
            <ForeName>Manon</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reeder</LastName>
            <ForeName>Stephen</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khan</LastName>
            <ForeName>Masood A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Christensen</LastName>
            <ForeName>Dennis</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Vaccine Research, Statens Serum Institute, DK-2300 Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pockley</LastName>
            <ForeName>Alan Graham</ForeName>
            <Initials>AG</Initials>
            <Identifier Source="ORCID">0000-0001-9593-6431</Identifier>
            <AffiliationInfo>
              <Affiliation>The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Health, Ageing and Understanding Disease (CHAUD), School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McArdle</LastName>
            <ForeName>Stéphanie E</ForeName>
            <Initials>SE</Initials>
            <Identifier Source="ORCID">0000-0001-6929-9782</Identifier>
            <AffiliationInfo>
              <Affiliation>The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Health, Ageing and Understanding Disease (CHAUD), School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancers (Basel)</MedlineTA>
        <NlmUniqueID>101526829</NlmUniqueID>
        <ISSNLinking>2072-6694</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CAF®09</Keyword>
        <Keyword MajorTopicYN="N">Dextramer™</Keyword>
        <Keyword MajorTopicYN="N">HHDII/DR1 mice</Keyword>
        <Keyword MajorTopicYN="N">PBMC</Keyword>
        <Keyword MajorTopicYN="N">castrate (hormone)-resistant PCa (CRPC)</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">prostate cancer</Keyword>
        <Keyword MajorTopicYN="N">prostatic acid phosphatase (PAP)</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>1</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35454873</ArticleId>
        <ArticleId IdType="pmc">PMC9032647</ArticleId>
        <ArticleId IdType="doi">10.3390/cancers14081970</ArticleId>
        <ArticleId IdType="pii">cancers14081970</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21660</ArticleId>
            <ArticleId IdType="pubmed">33538338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schymura M.J., Kahn A.R., German R.R., Hsieh M.-C., Cress R.D., Finch J.L., Fulton J.P., Shen T., Stuckart E. Factors Associated with Initial Treatment and Survival for Clinically Localized Prostate Cancer: Results from the CDC-NPCR Patterns of Care Study (PoC1) BMC Cancer. 2010;10:152.  doi: 10.1186/1471-2407-10-152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-10-152</ArticleId>
            <ArticleId IdType="pmc">PMC2876077</ArticleId>
            <ArticleId IdType="pubmed">20403178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNeel D.G., Bander N.H., Beer T.M., Drake C.G., Fong L., Harrelson S., Kantoff P.W., Madan R.A., Oh W.K., Peace D.J., et al.  The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Prostate Carcinoma. J. Immunother. Cancer. 2016;4:92. doi: 10.1186/s40425-016-0198-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-016-0198-x</ArticleId>
            <ArticleId IdType="pmc">PMC5170901</ArticleId>
            <ArticleId IdType="pubmed">28031820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Maeseneer D.J., Van Praet C., Lumen N., Rottey S. Battling Resistance Mechanisms in Antihormonal Prostate Cancer Treatment: Novel Agents and Combinations. Urol. Oncol. Semin. Orig. Investig. 2015;33:310–321. doi: 10.1016/j.urolonc.2015.01.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.urolonc.2015.01.008</ArticleId>
            <ArticleId IdType="pubmed">25708954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aly M., Leval A., Schain F., Liwing J., Lawson J., Vágó E., Nordström T., Andersson T.M.-L., Sjöland E., Wang C., et al.  Survival in Patients Diagnosed with Castration-Resistant Prostate Cancer: A Population-Based Observational Study in Sweden. Scand. J. Urol. 2020;54:115–121. doi: 10.1080/21681805.2020.1739139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21681805.2020.1739139</ArticleId>
            <ArticleId IdType="pubmed">32266854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirby M., Hirst C., Crawford E.D. Characterising the Castration-Resistant Prostate Cancer Population: A Systematic Review. Int. J. Clin. Pract. 2011;65:1180–1192. doi: 10.1111/j.1742-1241.2011.02799.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-1241.2011.02799.x</ArticleId>
            <ArticleId IdType="pubmed">21995694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., et al.  Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2010;363:411–422. doi: 10.1056/NEJMoa1001294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1001294</ArticleId>
            <ArticleId IdType="pubmed">20818862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H., Hong H., Li D., Ma S., Di Y., Stoten A., Haig N., Gleria K.D., Yu Z., Xu X.-N., et al.  Comparing Pooled Peptides with Intact Protein for Accessing Cross-Presentation Pathways for Protective CD8+ and CD4+ T Cells. J. Biol. Chem. 2009;284:9184–9191. doi: 10.1074/jbc.M809456200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M809456200</ArticleId>
            <ArticleId IdType="pmc">PMC2666570</ArticleId>
            <ArticleId IdType="pubmed">19193636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muniyan S., Chaturvedi N.K., Dwyer J.G., LaGrange C.A., Chaney W.G., Lin M.-F. Human Prostatic Acid Phosphatase: Structure, Function and Regulation. Int. J. Mol. Sci. 2013;14:10438–10464. doi: 10.3390/ijms140510438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms140510438</ArticleId>
            <ArticleId IdType="pmc">PMC3676848</ArticleId>
            <ArticleId IdType="pubmed">23698773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graddis T.J., McMahan C.J., Tamman J., Page K.J., Trager J.B. Prostatic Acid Phosphatase Expression in Human Tissues. Int. J. Clin. Exp. Pathol. 2011;4:295–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3071662</ArticleId>
            <ArticleId IdType="pubmed">21487525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saif J.M.S., Vadakekolathu J., Rane S.S., McDonald D., Ahmad M., Mathieu M., Pockley A.G., Durrant L., Metheringham R., Rees R.C., et al.  Novel Prostate Acid Phosphatase-Based Peptide Vaccination Strategy Induces Antigen-Specific T-Cell Responses and Limits Tumour Growth in Mice. Eur. J. Immunol. 2014;44:994–1004. doi: 10.1002/eji.201343863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201343863</ArticleId>
            <ArticleId IdType="pubmed">24338683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melief C.J.M., van der Burg S.H. Immunotherapy of Established (Pre)Malignant Disease by Synthetic Long Peptide Vaccines. Nat. Rev. Cancer. 2008;8:351–360. doi: 10.1038/nrc2373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2373</ArticleId>
            <ArticleId IdType="pubmed">18418403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bijker M.S., Eeden S.J.F.V.D., Franken K.L., Melief C.J.M., Offringa R., Van Der Burg S.H. CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, Whereas Long Peptides Induce Sustained CTL Reactivity. J. Immunol. 2007;179:5033–5040. doi: 10.4049/jimmunol.179.8.5033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.179.8.5033</ArticleId>
            <ArticleId IdType="pubmed">17911588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheiermann J., Klinman D.M. Clinical Evaluation of CpG Oligonucleotides as Adjuvants for Vaccines Targeting Infectious Diseases and Cancer. Vaccine. 2014;32:6377–6389. doi: 10.1016/j.vaccine.2014.06.065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.06.065</ArticleId>
            <ArticleId IdType="pmc">PMC4252359</ArticleId>
            <ArticleId IdType="pubmed">24975812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korsholm K.S., Hansen J., Karlsen K., Filskov J., Mikkelsen M., Lindenstrøm T., Schmidt S.T., Andersen P., Christensen D. Induction of CD8+ T-Cell Responses against Subunit Antigens by the Novel Cationic Liposomal CAF09 Adjuvant. Vaccine. 2014;32:3927–3935. doi: 10.1016/j.vaccine.2014.05.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.05.050</ArticleId>
            <ArticleId IdType="pubmed">24877765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajot A., Michel M.-L., Fazilleau N., Pancré V., Auriault C., Ojcius D.M., Lemonnier F.A., Lone Y.-C. A Mouse Model of Human Adaptive Immune Functions: HLA-A2.1-/HLA-DR1-Transgenic H-2 Class I-/Class II-Knockout Mice. Eur. J. Immunol. 2004;34:3060–3069. doi: 10.1002/eji.200425463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.200425463</ArticleId>
            <ArticleId IdType="pubmed">15468058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jurisic V. Multiomic Analysis of Cytokines in Immuno-Oncology. Expert Rev. Proteom. 2020;17:663–674. doi: 10.1080/14789450.2020.1845654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14789450.2020.1845654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cossarizza A., Chang H.-D., Radbruch A., Abrignani S., Addo R., Akdis M., Andrä I., Andreata F., Annunziato F., Arranz E., et al.  Guidelines for the Use of Flow Cytometry and Cell Sorting in Immunological Studies (Third Edition) Eur. J. Immunol. 2021;51:2708–3145. doi: 10.1002/eji.202170126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.202170126</ArticleId>
            <ArticleId IdType="pubmed">34910301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Özdemir Ö. Cell-Mediated Cytotoxicity Assays. Asthma Allergy Immunol. 2019;17:61–69. doi: 10.21911/aai.403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21911/aai.403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNeel D.G., Nguyen L.D., Ellis W.J., Higano C.S., Lange P.H., Disis M.L. Naturally Occurring Prostate Cancer Antigen-Specific T Cell Responses of a Th1 Phenotype Can Be Detected in Patients with Prostate Cancer. Prostate. 2001;47:222–229. doi: 10.1002/pros.1066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pros.1066</ArticleId>
            <ArticleId IdType="pubmed">11351352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machlenkin A., Paz A., Bar Haim E., Goldberger O., Finkel E., Tirosh B., Volovitz I., Vadai E., Lugassy G., Cytron S., et al.  Human CTL Epitopes Prostatic Acid Phosphatase-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy. Cancer Res. 2005;65:6435–6442. doi: 10.1158/0008-5472.CAN-05-0133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-0133</ArticleId>
            <ArticleId IdType="pubmed">16024648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voutsas I.F., Anastasopoulou E.A., Tzonis P., Papamichail M., Perez S.A., Baxevanis C.N. Unraveling the Role of Preexisting Immunity in Prostate Cancer Patients Vaccinated with a HER-2/Neu Hybrid Peptide. J. Immunother. Cancer. 2016;4:75. doi: 10.1186/s40425-016-0183-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-016-0183-4</ArticleId>
            <ArticleId IdType="pmc">PMC5109671</ArticleId>
            <ArticleId IdType="pubmed">27891225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olson B.M., Frye T.P., Johnson L.E., Fong L., Knutson K.L., Disis M.L., McNeel D.G. HLA-A2-Restricted T-Cell Epitopes Specific for Prostatic Acid Phosphatase. Cancer Immunol. Immunother. 2010;59:943–953. doi: 10.1007/s00262-010-0820-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-010-0820-6</ArticleId>
            <ArticleId IdType="pmc">PMC3038205</ArticleId>
            <ArticleId IdType="pubmed">20140431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peshwa M.V., Shi J.D., Ruegg C., Laus R., van Schooten W.C.A. Induction of Prostate Tumor-Specific CD8+ Cytotoxic T-Lymphocytes in Vitro Using Antigen-Presenting Cells Pulsed with Prostatic Acid Phosphatase Peptide. Prostate. 1998;36:129–138. doi: 10.1002/(SICI)1097-0045(19980701)36:2&lt;129::AID-PROS8&gt;3.0.CO;2-D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-0045(19980701)36:2&lt;129::AID-PROS8&gt;3.0.CO;2-D</ArticleId>
            <ArticleId IdType="pubmed">9655265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadaschik B., Su Y., Huter E., Ge Y., Hohenfellner M., Beckhove P. Antigen Specific T-Cell Responses Against Tumor Antigens Are Controlled by Regulatory T Cells in Patients With Prostate Cancer. J. Urol. 2012;187:1458–1465. doi: 10.1016/j.juro.2011.11.083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.juro.2011.11.083</ArticleId>
            <ArticleId IdType="pubmed">22341271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viganò S., Utzschneider D.T., Perreau M., Pantaleo G., Zehn D., Harari A. Functional Avidity: A Measure to Predict the Efficacy of Effector T Cells? Clin. Dev. Immunol. 2012;2012:e153863. doi: 10.1155/2012/153863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/153863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durrant L.G., Pudney V., Spendlove I., Metheringham R.L. Vaccines as Early Therapeutic Interventions for Cancer Therapy: Neutralising the Immunosuppressive Tumour Environment and Increasing T Cell Avidity May Lead to Improved Responses. Expert Opin. Biol. Ther. 2010;10:735–748. doi: 10.1517/14712591003769790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14712591003769790</ArticleId>
            <ArticleId IdType="pubmed">20384522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sckisel G.D., Mirsoian A., Minnar C.M., Crittenden M., Curti B., Chen J.Q., Blazar B.R., Borowsky A.D., Monjazeb A.M., Murphy W.J. Differential Phenotypes of Memory CD4 and CD8 T Cells in the Spleen and Peripheral Tissues Following Immunostimulatory Therapy. J. Immunother. Cancer. 2017;5:33. doi: 10.1186/s40425-017-0235-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0235-4</ArticleId>
            <ArticleId IdType="pmc">PMC5394626</ArticleId>
            <ArticleId IdType="pubmed">28428882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn E., Araki K., Hashimoto M., Li W., Riley J.L., Cheung J., Sharpe A.H., Freeman G.J., Irving B.A., Ahmed R. Role of PD-1 during Effector CD8 T Cell Differentiation. Proc. Natl. Acad. Sci. USA. 2018;115:4749–4754. doi: 10.1073/pnas.1718217115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1718217115</ArticleId>
            <ArticleId IdType="pmc">PMC5939075</ArticleId>
            <ArticleId IdType="pubmed">29654146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabins N.C., Chornoguz O., Leander K., Kaplan F., Carter R., Kinder M., Bachman K., Verona R., Shen S., Bhargava V., et al.  TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating MTORC1. J. Immunol. 2017;199:4091–4102. doi: 10.4049/jimmunol.1701030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1701030</ArticleId>
            <ArticleId IdType="pmc">PMC5713500</ArticleId>
            <ArticleId IdType="pubmed">29127145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elliot T.A.E., Jennings E.K., Lecky D.A.J., Thawait N., Flores-Langarica A., Copland A., Maslowski K.M., Wraith D.C., Bending D. Antigen and Checkpoint Receptor Engagement Recalibrates T Cell Receptor Signal Strength. Immunity. 2021;54:2481–2496. doi: 10.1016/j.immuni.2021.08.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2021.08.020</ArticleId>
            <ArticleId IdType="pmc">PMC8585507</ArticleId>
            <ArticleId IdType="pubmed">34534438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson A.C., Joller N., Kuchroo V.K. Lag-3, Tim-3, and TIGIT: Co-Inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016;44:989–1004. doi: 10.1016/j.immuni.2016.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.05.001</ArticleId>
            <ArticleId IdType="pmc">PMC4942846</ArticleId>
            <ArticleId IdType="pubmed">27192565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharpe A.H., Wherry E.J., Ahmed R., Freeman G.J. The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nat. Immunol. 2007;8:239–245. doi: 10.1038/ni1443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni1443</ArticleId>
            <ArticleId IdType="pubmed">17304234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konjević G.M., Vuletić A.M., Mirjačić Martinović K.M., Larsen A.K., Jurišić V.B. The Role of Cytokines in the Regulation of NK Cells in the Tumor Environment. Cytokine. 2019;117:30–40. doi: 10.1016/j.cyto.2019.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2019.02.001</ArticleId>
            <ArticleId IdType="pubmed">30784898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wherry E.J., Kurachi M. Molecular and Cellular Insights into T Cell Exhaustion. Nat. Rev. Immunol. 2015;15:486–499. doi: 10.1038/nri3862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3862</ArticleId>
            <ArticleId IdType="pmc">PMC4889009</ArticleId>
            <ArticleId IdType="pubmed">26205583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian S.L., Drake C.G., Pardoll D.M. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell. 2015;27:450–461. doi: 10.1016/j.ccell.2015.03.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.03.001</ArticleId>
            <ArticleId IdType="pmc">PMC4400238</ArticleId>
            <ArticleId IdType="pubmed">25858804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaveh D.A., Whelan A.O., Hogarth P.J. The Duration of Antigen-Stimulation Significantly Alters the Diversity of Multifunctional CD4 T Cells Measured by Intracellular Cytokine Staining. PLoS ONE. 2012;7:e38926.  doi: 10.1371/journal.pone.0038926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0038926</ArticleId>
            <ArticleId IdType="pmc">PMC3373578</ArticleId>
            <ArticleId IdType="pubmed">22719990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellis J.M., Henson V., Slack R., Ng J., Hartzman R.J., Katovich Hurley C. Frequencies of HLA-A2 Alleles in Five U.S. Population Groups: Predominance of A∗02011 and Identification of HLA-A∗0231. Hum. Immunol. 2000;61:334–340. doi: 10.1016/S0198-8859(99)00155-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0198-8859(99)00155-X</ArticleId>
            <ArticleId IdType="pubmed">10689125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fong L., Brockstedt D., Benike C., Breen J.K., Strang G., Ruegg C.L., Engleman E.G. Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy. J. Immunol. 2001;167:7150–7156. doi: 10.4049/jimmunol.167.12.7150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.167.12.7150</ArticleId>
            <ArticleId IdType="pubmed">11739538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolchok J.D., Yuan J., Houghton A.N., Gallardo H.F., Rasalan T.S., Wang J., Zhang Y., Ranganathan R., Chapman P.B., Krown S.E., et al.  Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma. Mol. Ther. 2007;15:2044–2050. doi: 10.1038/sj.mt.6300290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.mt.6300290</ArticleId>
            <ArticleId IdType="pubmed">17726460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qazilbash M.H., Wieder E., Thall P.F., Wang X., Rios R., Lu S., Kanodia S., Ruisaard K.E., Giralt S.A., Estey E.H., et al.  PR1 Peptide Vaccine Induces Specific Immunity with Clinical Responses in Myeloid Malignancies. Leukemia. 2017;31:697–704. doi: 10.1038/leu.2016.254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2016.254</ArticleId>
            <ArticleId IdType="pmc">PMC5332281</ArticleId>
            <ArticleId IdType="pubmed">27654852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson L.E., Olson B.M., McNeel D.G. Pretreatment Antigen-Specific Immunity and Regulation—Association with Subsequent Immune Response to Anti-Tumor DNA Vaccination. J. Immunother. Cancer. 2017;5:56. doi: 10.1186/s40425-017-0260-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0260-3</ArticleId>
            <ArticleId IdType="pmc">PMC5514519</ArticleId>
            <ArticleId IdType="pubmed">28716080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olson B.M., Jankowska-Gan E., Becker J.T., Vignali D.A.A., Burlingham W.J., McNeel D.G. Human Prostate Tumor Antigen-Specific CD8+ Regulatory T Cells Are Inhibited by CTLA-4 or IL-35 Blockade. J. Immunol. 2012;189:5590–5601. doi: 10.4049/jimmunol.1201744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1201744</ArticleId>
            <ArticleId IdType="pmc">PMC3735346</ArticleId>
            <ArticleId IdType="pubmed">23152566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farsaci B., Donahue R.N., Grenga I., Lepone L.M., Kim P.S., Dempsey B., Siebert J.C., Ibrahim N.K., Madan R.A., Heery C.R., et al.  Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunol. Res. 2016;4:755–765. doi: 10.1158/2326-6066.CIR-16-0037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-16-0037</ArticleId>
            <ArticleId IdType="pmc">PMC5138028</ArticleId>
            <ArticleId IdType="pubmed">27485137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santegoets S.J.A.M., Stam A.G.M., Lougheed S.M., Gall H., Scholten P.E.T., Reijm M., Jooss K., Sacks N., Hege K., Lowy I., et al.  T Cell Profiling Reveals High CD4+CTLA-4 + T Cell Frequency as Dominant Predictor for Survival after Prostate GVAX/Ipilimumab Treatment. Cancer Immunol. Immunother. 2013;62:245–256. doi: 10.1007/s00262-012-1330-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-012-1330-5</ArticleId>
            <ArticleId IdType="pubmed">22878899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santegoets S.J., Stam A.G., Lougheed S.M., Gall H., Jooss K., Sacks N., Hege K., Lowy I., Scheper R.J., Gerritsen W.R., et al.  Myeloid Derived Suppressor and Dendritic Cell Subsets Are Related to Clinical Outcome in Prostate Cancer Patients Treated with Prostate GVAX and Ipilimumab. J. Immunother. Cancer. 2014;2:31. doi: 10.1186/s40425-014-0031-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-014-0031-3</ArticleId>
            <ArticleId IdType="pmc">PMC4507359</ArticleId>
            <ArticleId IdType="pubmed">26196012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedersen G.K., Andersen P., Christensen D. Immunocorrelates of CAF Family Adjuvants. Semin. Immunol. 2018;39:4–13. doi: 10.1016/j.smim.2018.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.smim.2018.10.003</ArticleId>
            <ArticleId IdType="pubmed">30396811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahrends T., Spanjaard A., Pilzecker B., Bąbała N., Bovens A., Xiao Y., Jacobs H., Borst J. CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity. 2017;47:848–861. doi: 10.1016/j.immuni.2017.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2017.10.009</ArticleId>
            <ArticleId IdType="pubmed">29126798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts A.D., Ely K.H., Woodland D.L. Differential Contributions of Central and Effector Memory T Cells to Recall Responses. J. Exp. Med. 2005;202:123–133. doi: 10.1084/jem.20050137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050137</ArticleId>
            <ArticleId IdType="pmc">PMC2212898</ArticleId>
            <ArticleId IdType="pubmed">15983064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.R., Freeman G.J., Vignali D.A.A., Wherry E.J. Coregulation of CD8+ T Cell Exhaustion by Multiple Inhibitory Receptors during Chronic Viral Infection. Nat. Immunol. 2009;10:29–37. doi: 10.1038/ni.1679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1679</ArticleId>
            <ArticleId IdType="pmc">PMC2605166</ArticleId>
            <ArticleId IdType="pubmed">19043418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholz M., Yep S., Chancey M., Kelly C., Chau K., Turner J., Lam R., Drake C.G. Phase I Clinical Trial of Sipuleucel-T Combined with Escalating Doses of Ipilimumab in Progressive Metastatic Castrate-Resistant Prostate Cancer. Immunotargets. 2017;6:11–16. doi: 10.2147/ITT.S122497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/ITT.S122497</ArticleId>
            <ArticleId IdType="pmc">PMC5365325</ArticleId>
            <ArticleId IdType="pubmed">28361045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madan R.A., Mohebtash M., Arlen P.M., Vergati M., Rauckhorst M., Steinberg S.M., Tsang K.Y., Poole D.J., Parnes H.L., Wright J.J., et al.  Ipilimumab and a Poxviral Vaccine Targeting Prostate-Specific Antigen in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Dose-Escalation Trial. Lancet Oncol. 2012;13:501–508. doi: 10.1016/S1470-2045(12)70006-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(12)70006-2</ArticleId>
            <ArticleId IdType="pmc">PMC6359905</ArticleId>
            <ArticleId IdType="pubmed">22326924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jochems C., Tucker J.A., Tsang K.-Y., Madan R.A., Dahut W.L., Liewehr D.J., Steinberg S.M., Gulley J.L., Schlom J. A Combination Trial of Vaccine plus Ipilimumab in Metastatic Castration-Resistant Prostate Cancer Patients: Immune Correlates. Cancer Immunol. Immunother. 2014;63:407–418. doi: 10.1007/s00262-014-1524-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-014-1524-0</ArticleId>
            <ArticleId IdType="pmc">PMC6314199</ArticleId>
            <ArticleId IdType="pubmed">24514956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNeel D.G., Eickhoff J.C., Wargowski E., Zahm C., Staab M.J., Straus J., Liu G. Concurrent, but Not Sequential, PD-1 Blockade with a DNA Vaccine Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer. Oncotarget. 2018;9:25586–25596. doi: 10.18632/oncotarget.25387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.25387</ArticleId>
            <ArticleId IdType="pmc">PMC5986652</ArticleId>
            <ArticleId IdType="pubmed">29876010</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
